AbbVie Inc.$245.16LLY · NYSE
Consensus is Buy across 23 analysts, with a supplied mean price target of $1,300; consensus low and high targets were not provided. Third-party snapshots cluster around $1,217.79-$1,236.52 from StockAnalysis, MarketBeat and ChartMill, while higher averages include $1,350.33 from Benzinga and $1,350.89 from TipRanks. AnaChart shows the widest published spread, from $850 to $1,600. The evidence does not identify which analysts or firms set those extreme targets, so the most and least bullish individuals cannot be named; it does identify Citi’s Geoff Meacham as the most recent forecaster, dated July 15. No explicit rating or target revisions during the past week were supplied. The substantive disagreement is whether GLP-1 demand and pipeline catalysts outweigh earnings-guidance pressure and valuation risk.
